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Abstract
Background: Heart failure is a clinical syndrome that is associated with a significant number of
interventional procedures and has received a large amount of scrutiny in the adult literature;
however, the epidemiology in children is less well described.
Methods: We analyzed two large, commercially available inpatient datasets collected in 1997 by
the Agency for Healthcare Research and Quality: the Kids' Inpatient Database and the National
Inpatient Study, accounting for 50% of the U.S. pediatric discharges and 20% of the U.S. adult
discharges in 1997.
Results: The database contained 5,610 children and 732,752 adults with a diagnosis of HF. When
compared with the adult sample, the pediatric sample showed a higher proportion with cardiac
procedures (61.4% vs. 0.28%, p < 0.01), a higher prevalence of congenital heart disease (61% versus
0.3%, p < 0.01), a higher percentage of male patients (50% pediatric vs. 44% adult, p < 0.01), and a
lower percentage of white patients (40.9% vs. 65.6%, p < 0.01). Children had a significantly different
spectrum of co-morbidities compared with adults. There was no difference in mortality rate
between children and adults (7.5% vs. 7.9%, p = NS).
Conclusion: There are significant differences in the epidemiological profile of children and adults
with heart failure. Children suffer from different types of co-morbidities and require different
procedures in the hospital setting. As such, children with heart failure who are hospitalized may
require significantly different facilities, management and therapeutic intervention than adults with
similar symptoms.
Background
Heart failure (HF) is a well-recognized clinical syndrome
that affects both children and adults in the United States.
HF in adults has received considerable attention, with
multiple large, randomized trials that have evaluated the
etiology and therapy of this condition. For example, the
Framingham Heart Study has tracked data on adult car-
diac disease since 1948 and numerous more recent trials
have evaluated specific therapies for systolic dysfunction
[1-12]. However, the pediatric population is more diffi-
cult to study. It is difficult to enroll large numbers of chil-
dren in prospective studies, consent is more challenging
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to obtain and the definition of suitable endpoints remains
challenging.
Previous studies in children such as the 1985 Baltimore-
Washington Infant Study have described the incidence of
congenital heart disease, but have not focused on heart
failure [13]. Recently the Prospective Pediatric Cardiomy-
opathy Registry reported on the incidence of pediatric car-
diomyopathy (but not HF) in 2 regions of the United
States, suggesting an incidence of 1.13 cases per 100,000
children [14]. A population-based study conducted in Fin-
land over a longer time frame (11 years) had similar find-
ings [15]. However, heart failure due to other therapies
(chemotherapy-induced damage, or heart failure due to
congenital heart disease) was specifically excluded and
likely comprises a major component of pediatric HF [16].
Other studies of pediatric HF or cardiomyopathy have had
a limited sample size or have been from limited geo-
graphic regions [17-19].
The annual incidence of dilated cardiomyopathy in adults
is 2 to 8 cases per 100,000 in the US and Europe. The prev-
alence in adults in 1992 was estimated at 26 individuals
per 100,000 members of the population [20].
We are not aware of any comparisons between the charac-
teristics of adults with HF and children with HF. There are
no reports of complicating co-morbidities in these two
populations and the underlying prevalence of HF in these
populations has not been compared. Given the impor-
tance of understanding the differences between these pop-
ulations, we have examined a national database compiled
over one calendar year containing both pediatric and
adult admissions. From this database, we have taken all
known cases of heart failure and detailed the co-morbidi-
ties associated with the diagnosis, the types of procedures
that those patients receive, the length that they stay in the
hospital setting and the outcome of their hospital stays. In
doing so, we have highlighted some of the differences
between the adult and pediatric population with heart
failure.
Methods
Design and setting
We used two datasets in this study: the Kids' Inpatient
Database (KID) and the National Inpatient Study (NIS).
Both are commercially available datasets compiled by the
Agency for Healthcare Research and Quality (AHRQ) as
part of the Healthcare Utilization Project (HCUP). Both
databases are subsets of the same larger project. The data
were gathered and coded with identical methods. The KID
is a pediatric database that is culled from a larger dataset
that represents those admissions from 0 to 18 years of age.
The KID and NIS are nationwide databases that contain
inpatient stay information collected from hospital dis-
charge records. Both databases cover the calendar year
1997. These records are maintained by hospitals, state
agencies, and other private data organizations. These data
were collected from all discharges by each hospital, com-
piled by state data organizations and edited and checked
by AHRQ. Full documentation for the NIS and KID data-
bases is available through HCUP [21,22].
Patients and hospitals
The 1997 KID contains approximately 1.9 million pediat-
ric discharges, representing approximately 50% of the
pediatric discharges in the United States for the year 1997.
It includes data from 22 states. The 1997 NIS contains
approximately 7.1 million discharges of all ages from over
1,000 hospitals, containing approximately 20% of adult
discharges in the United States for the year 1997.
In both datasets, the included hospitals range from major
teaching hospitals to community hospitals. Both datasets
include information on all patients, regardless of payer,
including those covered by Medicaid, private insurance
and the uninsured. Data is grouped into over 100 catego-
ries, covering both clinical and non-clinical information.
All data files contained a principal diagnosis as coded by
the physician or staff member at discharge as well as up to
14 additional diagnoses for each case. All data files con-
tained up to 15 procedure codes, identified by ICD-9-CM
code.
Data collection
Diagnoses consistent with heart failure were identified
using the International Classification of Disease code
(ICD-9-CM). We included ICD-9 codes 398.91 (rheu-
matic heart failure, congestive); 402.01, 402.11, and
402.91 (hypertensive heart disease with congestive heart
failure); 404.01, 404.11, 404.91, 404.03, 404.13, and
404.93 (hypertensive heart and renal disease with conges-
tive heart failure); 428.xx (congestive heart failure); and
429.4 (cardiac failure following surgery, excluding imme-
diate postoperative failure [997.1]). Each diagnostic code
was converted to a diagnostic category based on the Clin-
ical Classification Software (CCS) available from the
HCUP website. After the initial selection by ICD-9 code,
all subsequent analysis was based on these CCS codings.
Relevant procedures were identified using the CCS. Full
documentation on CCS has been described by HCUP pre-
viously [23].
Analysis
The population was divided into three groups, those
under one year of age (infants), those between one and 18
years of age (children), and those over 18 years of age
(adults). These criteria were chosen prior to analysis based
on the clinical observation that the etiology of heart fail-
ure differs before and after one year of age [14]. Where theBMC Cardiovascular Disorders 2006, 6:23 http://www.biomedcentral.com/1471-2261/6/23
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two pediatric groups were not significantly different, the
results were pooled to simplify presentation of the data.
Cases were analyzed for the number of co-morbid diag-
noses in each group. Co-morbid diagnoses were divided
into system-based categories and all CCS diagnostic codes
were assigned to a system-based category by the authors.
The CCS procedure codes were similarly divided by the
authors into system-based categories with a large "miscel-
laneous" category that contained both non-classifiable
procedures and those procedures that were classifiable
into multiple system-based categories.
Chi square analysis was utilized to compare the adult and
pediatric populations in all categorical variables. Sub-test-
ing was done using the Yates correction and the Bonfer-
roni inequality was used to allow for the fact that multiple
comparisons were being done. For continuous variables,
ANOVA testing was used.
Results and discussion
We identified 5,610 people 18 years old or less and
732,752 people greater than 18 years old with heart fail-
ure. In our sample population, 3,176 children were
younger than one year of age (infants). HF was the pri-
mary diagnosis in 564 infants (18%) and was a secondary
diagnosis in 2,612 infants (82%). There were 2,434
patients between one year and 18 years of age (children).
HF was the primary diagnosis in 614 children (25%) and
was a secondary diagnosis in the remaining 1,820 chil-
dren (75%).
The data on gender are summarized in Table 1. Unlike in
older patients, where there is a substantial over-represen-
tation of female patients, we find that children have a
nearly identical proportion of male and female patients.
The pediatric sample (ages 0–18) had a significantly
greater percentage of non-white patients when compared
to their adult counterparts (Table 2). However, in both
pediatric and adult groups, whites make up the greatest
number overall, followed by blacks and then Hispanics.
Note that the numbers do not sum to 100% since not all
patients in the database were assigned a code for race at
the time of discharge.
Pediatric hospital length of stay was appreciably longer
than adults, with infants having the longest stays (Table
3). The presence or absence of heart failure as a primary
diagnosis did not reliably predict length of stay across the
three groups.
Many patients were also documented as having important
co-morbidities. As would be expected, the incidence of
congenital cardiac disease was greater in both infants and
children when compared with the adult population.
However, there was a striking decrease in the incidence of
congenital cardiac disease in children when compared
with infants, which may be due to the likelihood of hav-
ing congenital defects repaired in infancy, reducing the
likelihood of hospitalization due to left to right shunting
lesions. Infants and children have a high incidence of
non-cardiac congenital lesions. The other identified diag-
nostic categories are summarized in Table 4.
The frequency of cardiac procedures is shown in Table 5.
Pediatric patients have a higher proportion of cardiac
bypass procedures when compared with adult patients.
This underscores the high prevalence of surgical manage-
ment for serious structural problems in pediatrics. The
rates of intubation are significantly higher in pediatrics
than in adults, which probably reflects the increased prev-
alence of surgical management in pediatrics. In addition,
cardiac transplantation, while infrequent in all age
groups, was significantly more common in children than
in adults.
Not surprisingly, stays that required the use of cardiover-
sion were associated with increased risk of mortality in all
age groups. Findings for intubation were similar. These
data are shown in Table 6.
There was no difference in overall mortality between chil-
dren and adults (7.5% vs. 7.9%, p = NS), which is proba-
bly a serendipitous finding given the significant
differences in etiologies, co-morbidities, and treatment
approaches between the two groups.
We describe here differences between pediatric and adult
heart failure patients in the hospital setting. It is challeng-
ing to gather pediatric data that can be directly compared
Table 1: Gender Comparison
Gender (%)
Age Group Male Female
Age 0 – 18 2792 (49.8) 2817 (50.2)
Age > 18 323972 (44.2) 408737 (55.8)
p-value <0.01 <0.01BMC Cardiovascular Disorders 2006, 6:23 http://www.biomedcentral.com/1471-2261/6/23
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against adult data since almost all large trials have been
exclusively in the adult population. We have explored a
single database, designed for financial data gathering;
and, from there, we have extracted relevant clinical infor-
mation to compare the two populations. Since it is only in
the last several years that data of this type have been made
available, this has rarely been done previously and never
in HF to our knowledge.
Clear differences exist between pediatric and adult HF
patients. The overall difference between the numbers of
procedures that children undergo versus adults is striking.
A likely cause for this difference is the discrepancy
between the frequencies of congenital heart disease in the
two populations. Our study supports the observation that
congenital heart disease is a common causative factor in
pediatric heart failure, while it is a much less common rea-
son for HF in adults. As the number of adults with
repaired congenital heart disease increases, the number of
cases of HF in adults due to congenital heart disease will
also increase, but our data suggest that – despite this antic-
ipated growth – congenital heart disease is not likely to
become a common cause of HF in adults.
In addition, the prevalence of other congenital anomalies
(including non-cardiac) is higher in hospitalized children
than in hospitalized adults. There are three reasons that
may account for this observation. First, patients with
other congenital disorders may have excess childhood
mortality and would therefore not be included in adult
samples. In addition, there may be a recording bias
toward classifying problems as congenital by the physi-
cians who care for children. Finally, coronary artery dis-
ease is a major cause of HF and subsequent
hospitalization in adults but it is rare in children, and this
etiology is presumably not related to the presence of con-
genital anomalies.
Our study suggests that there are other significant differ-
ences between children and adults with HF. Adults are sig-
nificantly more likely to have neurological, hematological
and oncologic, infectious disease, renal and endocrine
abnormalities, suggesting that adults are often sick with
multi-system disease that may not be directly linked to the
etiology of their heart failure. However, the association
between HF and other congenital diseases in children sug-
gests that children may be more likely to have syndromic
conditions that influence their outcome. Further study is
necessary to determine what percentage of children and
adults have significant mortality due to those co-morbid-
ities.
While in the hospital, children were significantly more
likely than adults to undergo intubation, cardiac bypass,
cardioversion and other cardiac procedures. Hospital
stays were significantly longer in the pediatric population,
perhaps due to the surgical management of major struc-
tural anomalies. In contrast, adults with HF experienced a
low utilization of intubation, cardiac bypass and other
cardiac procedures, suggesting that the major components
of their regimen were medical, as opposed to surgical,
therapies.
A major limitation of our study lies in the fact that we had
access only to a large, commercially available dataset.
Therefore, it was impossible to correlate specific diagnoses
with chart review since we had no access to individual
patient documentation. Similarly, since the dataset was
Table 3: Age and Length of Stay
Age (years) Length of Stay (days)
0 – 1 15.52*
≥1 and ≤18 11.1*
> 18 7.43*
* All comparisons p < 0.01 versus the other two comparison groups.
Table 2: Racial Demographics
Races comprising Non-white Category
Age Group White Non-white Black Hispanic Asian/Pacific
Islander
Native
American
Other
Age 0 – 18 2295 (40.9) 1970 (35.1) 797 (14.2) 757 (13.5) 178 (3.2) 28 (0.5) 210 (3.7)
Age > 18 480867 (65.6) 111624 (15.2) 69520 (9.5) 29980 (4.1) 5488 (0.7) 766 (0.1) 5870 (0.8)
p-value < 0.01 < 0.01
Note: numbers in parenthesis represent % of total population in each age rangeBMC Cardiovascular Disorders 2006, 6:23 http://www.biomedcentral.com/1471-2261/6/23
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primarily designed for utilization analysis, we were una-
ble to further subdivide the operative procedures into sub-
categories that would allow us to describe specific
interventions. However, the benefit of using a large, if cat-
egorically limited, dataset is that it allows us a well-pow-
ered study. This study indicates that the significant
differences in interventions in patients with heart failure
suggest that the etiology, and therefore subsequent care,
of children's heart failure differ significantly between chil-
dren and adults.
Conclusion
We have found that significantly different interventions
are utilized for children and adults in the hospital setting.
As such, children with heart failure who are hospitalized
may require significantly different facilities, management
and therapeutic intervention than adults with similar
symptoms. Given the high rate of procedural interven-
tions for children with congestive heart failure, close col-
laboration between cardiologists and cardiothoracic
surgeons is imperative to optimize care for these children.
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* P-value is due to variability between pediatric patients (age 0 – 18 years) and adults (age > 18 years).
Table 4: Subspecialty Comorbid Diagnoses
Percent of patients with diagnosis
Diagnosis Age < 1 yr Age ≥ 1 yr and ≤ 18 yr Age >18 yr Infants vs. Children p-
value*
Pediatric vs. Adult p-
value+
Congenital, Cardiac 82.27%3 4 . 2 6 %0 . 2 8 % < 0 . 0 1 < 0 . 0 1
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